Palvella Therapeutics (PVLA) Net Cash Flow (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Net Cash Flow of $148.4 million for Q1 2026, up 1961.87% year-over-year from $7.2 million in Q1 2025, and up 3094.77% quarter-over-quarter from -$5.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Net Cash Flow (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Net Cash Flow for 14 consecutive years, with $148.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1961.87% year-over-year to $148.4 million; the TTM figure through Mar 2026 stood at $130.7 million (up 82.28% YoY), while the FY2025 annual figure was -$25.7 million, down 133.66% from the prior year.
- Net Cash Flow advanced to $148.4 million in Q1 2026 per PVLA's latest filing, from -$5.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $148.4 million in Q1 2026 and bottomed at -$33.0 million in Q1 2022.
- Historically, Net Cash Flow has averaged $8.2 million across 5 years, with a median of -$3.0 million in 2022.
- Annual changes were most pronounced in 2025 — Net Cash Flow plunged 3973.4% — and 2026, when it soared 1961.87%.
- Palvella Therapeutics' Net Cash Flow stood at -$11.7 million in 2022, then soared by 177.69% to $9.1 million in 2023, then soared by 661.29% to $69.4 million in 2024, then sank by 107.14% to -$5.0 million in 2025, then jumped by 3094.77% to $148.4 million in 2026.
- Business Quant data shows PVLA's Net Cash Flow at $148.4 million in Q1 2026, -$5.0 million in Q4 2025, and -$7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | -18.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.56 Mn |
| Jun 30, 2026 | -18.56 Mn |
| Mar 31, 2026 | 148.39 Mn |
| Mar 31, 2026 | 148.39 Mn |
| Dec 31, 2025 | -4.96 Mn |
| Dec 31, 2025 | -4.96 Mn |
| Sep 30, 2025 | -7.66 Mn |
| Sep 30, 2025 | -7.66 Mn |
| Jun 30, 2025 | -5.08 Mn |
| Jun 30, 2025 | -5.08 Mn |
| Mar 31, 2025 | -7.97 Mn |
| Mar 31, 2025 | -7.97 Mn |
| Dec 31, 2024 | 69.39 Mn |
| Dec 31, 2024 | 69.39 Mn |
| Sep 30, 2024 | -188,000.00 |
| Sep 30, 2024 | -188,000.00 |
| Jun 30, 2024 | 10.47 Mn |
| Jun 30, 2024 | 10.47 Mn |
| Mar 31, 2024 | 7.90 Mn |
| Mar 31, 2024 | 7.90 Mn |